Inflammatory Markers
No guideline will adequately capture the minutiae of rationale for inflammatory marker testing. The Blood Sciences Department are happy to discuss or clarify individual issues as they arise; please direct queries to rch-tr.haematology-lab@nhs.net
CRP should be your first line inflammatory marker test of choice.
ESR testing is no longer offered.
There are not many situations where good clinical correlation with (or without) the CRP cannot guide patient management. If a second line inflammatory marker is required we will send plasma viscosity (PV) to University Hospital Plymouth. This test will carry an expected 2-4 day turnaround time.
PV should not be requested automatically for routine situations where the ESR was used previously. We will be consciously discouraging unnecessary PV requests. We will be monitoring our test volumes alongside any specific concerns that have been flagged by our users.
ICE will be set up to allow specification of PV request rationale:
-
If temporal arteritis (TA)/giant cell arteritis (GCA) or hyperviscosity syndrome is suspected then PV, although not necessary, may be requested. Appropriate management of these indications should not be delayed while results are pending
-
If a systemic inflammatory illness such as rheumatoid arthritis or systemic lupus erythematosus is suspected and CRP is normal then PV may be appropriate to establish a baseline for monitoring
- If CRP has been shown to inadequately reflect disease activity in a patient with established chronic inflammatory illness (such as rheumatoid arthritis or systemic lupus erythematosus) then monitoring with PV will be appropriate.
There is room to select ‘Other’ as the rationale for your PV request if it does not fall within these criteria. These will be vetted on a case-by-case basis. We aim not to be obstructive, but if clinical details are inadequate we will store the sample pending further information.
References
- Haematology Site Specific Group, Advice and Guidance for non-Haematological Clinicians, October 2024
Page Review Information
Date reviewed: 15 July 2025
Date next review: 15 July 2027
Clinical Editors: Dr L Lomas
Contributors: Dr Michelle Furtado, Peninsula Cancer Alliance, HSSG